In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility-Reference-Cited by-同舟云学术

In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility

Published:2006-11 Issue:11 Volume:50 Page:3926-3928
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cota Jason¹²,Carden Michael²,Graybill John R.²,Najvar Laura K.²,Burgess David S.¹²,Wiederhold Nathan P.¹²

Affiliation:

1. The University of Texas at Austin College of Pharmacy, Austin, Texas

2. The University of Texas Health Science Center at San Antonio, San Antonio, Texas

Abstract

ABSTRACT The activities of anidulafungin and caspofungin against Candida glabrata were evaluated. MICs, 50% inhibitory concentrations (IC 50 values), and IC 90 values for anidulafungin were lower than those for caspofungin for 16 of 18 strains tested. Anidulafungin has potent in vitro activity against C. glabrata that is maintained against isolates with elevated caspofungin MICs.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00538-06

Reference30 articles.

1. Arevalo, M. P., A. J. Carrillo-Munoz, J. Salgado, D. Cardenes, S. Brio, G. Quindos, and A. Espinel-Ingroff. 2003. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother.51:163-166.

2. Bodey, G. P., M. Mardani, H. A. Hanna, M. Boktour, J. Abbas, E. Girgawy, R. Y. Hachem, D. P. Kontoyiannis, and I. I. Raad. 2002. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med.112:380-385.

3. Dowell, J. A., W. Knebel, T. Ludden, M. Stogniew, D. Krause, and T. Henkel. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol.44:590-598.

4. Dowell, J. A., M. Stogniew, D. Krause, T. Henkel, and I. E. Weston. 2005. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol.45:227-233.

5. Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2022-02

2. Resistance to Antifungal Drugs;Infectious Disease Clinics of North America;2021-06

3. Criteria for the administration of systemic antimicotic therapy in surgical intensive care units (literature review);Pelvic Surgery and Oncology;2019-11-13

4. KRE5 Suppression Induces Cell Wall Stress and Alternative ER Stress Response Required for Maintaining Cell Wall Integrity in Candida glabrata;PLOS ONE;2016-08-22

5. Echinocandins: The Expanding Antifungal Armamentarium;Clinical Infectious Diseases;2015-11-05